IGM Biosciences Initiated at Outperform by BMO Capital
BMO Capital Initiates IGM Biosciences(IGMS.US) With Buy Rating, Announces Target Price $21
IGM Biosciences Analyst Ratings
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $27
RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
IGM Biosciences Analyst Ratings
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), IGM Biosciences (IGMS)
RBC Capital Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $20
A Quick Look at Today's Ratings for IGM Biosciences(IGMS.US), With a Forecast Between $9 to $25
IGM Biosciences Is Maintained at Buy by Guggenheim
Wedbush Maintains Outperform on IGM Biosciences, Lowers Price Target to $22
IGM Biosciences Cut to Hold From Buy by Truist Securities
IGM Biosciences Price Target Cut to $12.00/Share From $24.00 by Truist Securities
IGM Biosciences Analyst Ratings
A Quick Look at Today's Ratings for IGM Biosciences(IGMS.US), With a Forecast Between $9 to $48
RBC Capital Remains a Buy on IGM Biosciences (IGMS)
JPMorgan Downgrades IGM Biosciences to Underweight From Neutral, Adjusts Price Target to $9 From $12
IGM Biosciences: Hold Rating Amidst Strategic Shift and Leadership Changes
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Announces Target Price $25
Analysts Are Bullish on These Healthcare Stocks: IGM Biosciences (IGMS), 4D Molecular Therapeutics (FDMT)